Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
SIGA Technologies is a commercial-stage pharmaceutical company focused on biodefense, with its primary asset being TPOXX (tecovirimat), an FDA-approved antiviral treatment for smallpox and orthopoxviruses including monkeypox. The company operates primarily through government procurement contracts with BARDA (Biomedical Advanced Research and Development Authority) and international health agencies, generating revenue from stockpile purchases and delivery orders rather than traditional commercial pharmaceutical sales. Stock performance is driven by government contract awards, geopolitical biodefense spending priorities, and outbreak-related demand spikes.
SIGA generates revenue through multi-year procurement contracts with government agencies that maintain strategic national stockpiles of TPOXX for biodefense preparedness. The business model is characterized by lumpy, contract-driven revenue recognition with high gross margins (77%) due to minimal manufacturing costs once development is complete. Pricing power derives from TPOXX being the only FDA-approved smallpox antiviral, creating a monopolistic position in a government-funded niche market. Revenue timing depends on contract modifications, delivery schedules, and appropriations rather than traditional market demand dynamics.
New BARDA contract awards or modifications (size, duration, pricing terms)
International procurement announcements from NATO allies or WHO-affiliated agencies
Outbreak events involving orthopoxviruses (monkeypox, cowpox) driving emergency use demand
US federal budget appropriations for biodefense and pandemic preparedness programs
Clinical trial results for label expansions or new indications beyond smallpox
Single-product dependency on TPOXX creates existential risk if government stockpile strategies shift away from smallpox preparedness or alternative antivirals gain approval
Government budget prioritization risk as biodefense competes with other national security and healthcare spending, particularly during fiscal consolidation periods
Patent expiration risk (key patents expire 2028-2032) could enable generic competition and erode pricing power in government procurement
Emergence of competing orthopoxvirus antivirals in clinical development by larger pharmaceutical companies with superior government relationships
Shift in government procurement strategy toward broader-spectrum antivirals or vaccine-only approaches for smallpox preparedness
Revenue concentration and lumpiness creates cash flow volatility - company must maintain sufficient reserves between major contract awards
Minimal balance sheet risk given zero debt, 9.17x current ratio, and strong cash generation, but working capital needs fluctuate with contract timing
low - Revenue is driven by government biodefense budgets and geopolitical threat assessments rather than GDP growth or consumer spending. Federal appropriations for pandemic preparedness show minimal correlation to economic cycles, though severe fiscal constraints could impact discretionary defense spending.
Rising rates have moderate negative impact on valuation multiples for this cash-generative, low-growth biodefense stock, as investors discount future contract cash flows more heavily. However, the business itself has minimal interest rate exposure with zero debt and substantial cash reserves ($94M+ based on 9.17x current ratio). Higher rates may marginally increase treasury income on cash holdings.
Minimal - counterparty risk is limited to US government and sovereign entities with negligible default probability. No reliance on commercial credit markets or consumer financing.
value - Attracts deep-value and special situations investors focused on cash-generative, asset-light businesses trading below intrinsic value. The 10% FCF yield, 3.3x EV/EBITDA, and zero debt appeal to value-oriented funds, while biodefense contract optionality provides asymmetric upside. Not suitable for growth investors given -0.9% revenue growth and single-product maturity. Event-driven funds may trade around contract announcements and outbreak catalysts.
high - Stock exhibits significant volatility driven by binary contract announcement outcomes and outbreak-related sentiment swings. Small market cap ($500M) and low float amplify price movements. Recent performance shows 13.6% gain over 3 months but -24% over 6 months, reflecting event-driven trading patterns rather than fundamental business volatility.
